Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:9119
Name acute myeloid leukemia
Definition A myeloid leukemia that is characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells.
Source DiseaseOntology.org
Alt Ids DOID:9118 DOID:9171
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia myeloid leukemia acute myeloid leukemia

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FLT3 E598_Y599insGLVQVTGSSDNEYFYVDFREYE Tandutinib acute myeloid leukemia sensitive detail...
FLT3 E612_F613insGYVDFREYEYDLKWEFRPRENLEF Tandutinib acute myeloid leukemia sensitive detail...
FLT3 R595_L601dup Tandutinib acute myeloid leukemia sensitive detail...
FLT3 L611_E612insCSSDNEYFYVDFREYEYDLKWEFPRENL Tandutinib acute myeloid leukemia sensitive detail...
FLT3 Y599_D600insGLYVDFREYEY Tandutinib acute myeloid leukemia sensitive detail...
IDH2 R140Q AGI-6780 acute myeloid leukemia sensitive detail...
ETV6 - NTRK3 Crizotinib acute myeloid leukemia sensitive detail...
NPM1 exon12 Deguelin acute myeloid leukemia sensitive detail...
JAK2 V617F Go6976 acute myeloid leukemia sensitive detail...
JAK2 V617F A-1155463 acute myeloid leukemia sensitive detail...
IDH1 R132C Ivosidenib acute myeloid leukemia sensitive detail...
FLT3 D835H Crenolanib acute myeloid leukemia sensitive detail...
FLT3 Y842C Midostaurin acute myeloid leukemia sensitive detail...
FLT3 Y842C Imatinib acute myeloid leukemia resistant detail...
NPM1 mutant NSC348884 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Ponatinib acute myeloid leukemia sensitive detail...
FLT3 act mut Cytarabine + Daunorubicin + Sunitinib acute myeloid leukemia sensitive detail...
CTNNB1 amp CWP232291 acute myeloid leukemia predicted - sensitive detail...
ETV6 - NTRK3 Larotrectinib acute myeloid leukemia sensitive detail...
TET2 mutant Azacitidine acute myeloid leukemia predicted - sensitive detail...
FLT3 mutant Cytarabine + Daunorubicin + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 wild-type Cytarabine + Daunorubicin + Midostaurin acute myeloid leukemia sensitive detail...
Unknown unknown BAY 1238097 acute myeloid leukemia not applicable detail...
RUNX1 mutant N/A acute myeloid leukemia not applicable detail...
DNMT3A mutant N/A acute myeloid leukemia not applicable detail...
DNMT3A mut FLT3 mut NPM1 mut N/A acute myeloid leukemia not applicable detail...
FLT3 Y599_D600insSTDNEYFYVDFREYEY Azacitidine + Sorafenib acute myeloid leukemia predicted - sensitive detail...
FLT3 mutant Gilteritinib acute myeloid leukemia sensitive detail...
FLT3 act mut Crenolanib acute myeloid leukemia sensitive detail...
FLT3 Y599_D600insSTDNEYFYVDFREYEY E6201 acute myeloid leukemia predicted - sensitive detail...
FLT3 Y599_D600insSTDNEYFYVDFREYEY FLX925 acute myeloid leukemia predicted - sensitive detail...
FLT3 mutant Azacitidine + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 Y599_D600insSTDNEYFYVDFREYEY IDH2 R140W Enasidenib + Quizartinib acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins Pacritinib acute myeloid leukemia predicted - sensitive detail...
NRAS G12D Binimetinib acute myeloid leukemia sensitive detail...
FLT3 Y599_D600insSTDNEYFYVDFREYEY Quizartinib acute myeloid leukemia predicted - sensitive detail...
NRAS G12D Alpelisib + Binimetinib acute myeloid leukemia sensitive detail...
CEBPA mut GATA2 mut N/A acute myeloid leukemia not applicable detail...
KIT D816V Cytarabine + Dasatinib acute myeloid leukemia sensitive detail...
FLT3 mutant UNC2025 acute myeloid leukemia sensitive detail...
FGFR1 fusion Dovitinib acute myeloid leukemia sensitive detail...
Unknown unknown SST0116CL1 acute myeloid leukemia not applicable detail...
Unknown unknown Forskolin acute myeloid leukemia not applicable detail...
Unknown unknown Cytarabine + Daunorubicin + Debio 1143 acute myeloid leukemia not applicable detail...
Unknown unknown CX-6258 acute myeloid leukemia not applicable detail...
Unknown unknown Cytarabine + LGH447 acute myeloid leukemia not applicable detail...
Unknown unknown AZD1897 + Capivasertib acute myeloid leukemia not applicable detail...
Unknown unknown INCB053914 acute myeloid leukemia not applicable detail...
Unknown unknown RG7112 acute myeloid leukemia not applicable detail...
JAK2 V617F RP6530 + Ruxolitinib acute myeloid leukemia sensitive detail...
Unknown unknown RO3280 acute myeloid leukemia not applicable detail...
KMT2A - MLLT1 NRAS G12D Dinaciclib acute myeloid leukemia sensitive detail...
KMT2A - MLLT3 Dinaciclib acute myeloid leukemia sensitive detail...
KMT2A - AFF1 Dinaciclib acute myeloid leukemia sensitive detail...
NPM1 mutant N/A acute myeloid leukemia not applicable detail...
Unknown unknown ST7612AA1 acute myeloid leukemia not applicable detail...
Unknown unknown Birabresib acute myeloid leukemia not applicable detail...
IDH1 mutant N/A acute myeloid leukemia not applicable detail...
RUNX1 - RUNX1T1 N/A acute myeloid leukemia not applicable detail...
RUNX1 - RUNX1T1 KIT mut N/A acute myeloid leukemia not applicable detail...
CEBPA mutant N/A acute myeloid leukemia not applicable detail...
Unknown unknown Guadecitabine acute myeloid leukemia not applicable detail...
GATA2 mutant N/A acute myeloid leukemia not applicable detail...
KMT2A rearrange N/A acute myeloid leukemia not applicable detail...
TET2 mutant N/A acute myeloid leukemia not applicable detail...
FLT3 mutant E6201 acute myeloid leukemia sensitive detail...
FLT3 act mut Palbociclib acute myeloid leukemia sensitive detail...
FLT3 wild-type Palbociclib acute myeloid leukemia sensitive detail...
FLT3 act mut Palbociclib + TCS 359 acute myeloid leukemia sensitive detail...
FLT3 wild-type Palbociclib + TCS 359 acute myeloid leukemia sensitive detail...
FLT3 act mut TCS 359 acute myeloid leukemia sensitive detail...
FLT3 wild-type TCS 359 acute myeloid leukemia sensitive detail...
FLT3 act mut Palbociclib + Quizartinib acute myeloid leukemia sensitive detail...
FLT3 act mut Palbociclib + Tandutinib acute myeloid leukemia sensitive detail...
FLT3 act mut Palbociclib + SGI-1776 acute myeloid leukemia sensitive detail...
NRAS mutant LY3009120 acute myeloid leukemia sensitive detail...
NRAS mutant Trametinib acute myeloid leukemia sensitive detail...
FLT3 mutant Crenolanib acute myeloid leukemia sensitive detail...
FLT3 D835X Crenolanib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Crenolanib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 D835X Crenolanib acute myeloid leukemia sensitive detail...
Unknown unknown GS87 acute myeloid leukemia not applicable detail...
FLT3 D835Y E6201 acute myeloid leukemia sensitive detail...
FLT3 D835G E6201 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins E6201 acute myeloid leukemia sensitive detail...
DNMT3A mutant Decitabine acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins SHP099 acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins Quizartinib acute myeloid leukemia sensitive detail...
Unknown unknown Pexmetinib acute myeloid leukemia not applicable detail...
Unknown unknown ENMD-2076 acute myeloid leukemia not applicable detail...
FLT3 exon 14 ins ENMD-2076 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins NPM1 mut ENMD-2076 acute myeloid leukemia sensitive detail...
NPM1 mutant ENMD-2076 acute myeloid leukemia sensitive detail...
IDH1 mutant Venetoclax acute myeloid leukemia predicted - sensitive detail...
IDH2 mutant Venetoclax acute myeloid leukemia predicted - sensitive detail...
IDH2 D76fs Venetoclax acute myeloid leukemia sensitive detail...
Unknown unknown Venetoclax acute myeloid leukemia not applicable detail...
Unknown unknown Bortezomib + Cytarabine + Etoposide + Midostaurin + Mitoxantrone acute myeloid leukemia not applicable detail...
Unknown unknown Daunorubicin + Venetoclax acute myeloid leukemia predicted - sensitive detail...
Unknown unknown CPI-0610 + Doxorubicin acute myeloid leukemia not applicable detail...
KIT N822K Ripretinib acute myeloid leukemia sensitive detail...
KIT N822K BPR1J373 acute myeloid leukemia sensitive detail...
KIT wild-type BPR1J373 acute myeloid leukemia sensitive detail...
FLT3 act mut VS-5584 acute myeloid leukemia sensitive detail...
Unknown unknown Erlotinib + Ethacridine acute myeloid leukemia not applicable detail...
Unknown unknown MT1 acute myeloid leukemia not applicable detail...
NRAS mutant AZD5153 acute myeloid leukemia predicted - sensitive detail...
KMT2A - AFF1 AZD5153 acute myeloid leukemia predicted - sensitive detail...
Unknown unknown ONC201 acute myeloid leukemia not applicable detail...
Unknown unknown ONC201 + Venetoclax acute myeloid leukemia not applicable detail...
Unknown unknown (-)BI97D6 acute myeloid leukemia not applicable detail...
FLT3 exon 14 ins MRX-2843 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 D835Y MRX-2843 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 F691L MRX-2843 acute myeloid leukemia sensitive detail...
Unknown unknown T-3775440 acute myeloid leukemia not applicable detail...
Unknown unknown TTI-621 acute myeloid leukemia not applicable detail...
IDH1 R132X IDH305 acute myeloid leukemia sensitive detail...
Unknown unknown Carboplatin + Topotecan + Veliparib acute myeloid leukemia not applicable detail...
FLT3 exon 14 ins Altiratinib acute myeloid leukemia sensitive detail...
Unknown unknown MLN4924 acute myeloid leukemia not applicable detail...
Unknown unknown INCB054329 + INCB059872 acute myeloid leukemia not applicable detail...
Unknown unknown Barasertib acute myeloid leukemia not applicable detail...
Unknown unknown AMG 900 acute myeloid leukemia not applicable detail...
Unknown unknown AZD2811 acute myeloid leukemia not applicable detail...
Unknown unknown Alisertib acute myeloid leukemia not applicable detail...
Unknown unknown RN-1 acute myeloid leukemia not applicable detail...
RUNX1 - RUNX1T1 RN-1 acute myeloid leukemia sensitive detail...
RUNX1 - RUNX1T1 GSK690 acute myeloid leukemia sensitive detail...
Unknown unknown RN-1 + Tretinoin acute myeloid leukemia not applicable detail...
Unknown unknown CPI-169 + RN-1 acute myeloid leukemia not applicable detail...
Unknown unknown Cytarabine + RN-1 acute myeloid leukemia not applicable detail...
Unknown unknown BI 836858 + Decitabine acute myeloid leukemia not applicable detail...
Unknown unknown BI 836858 acute myeloid leukemia not applicable detail...
Unknown unknown MK-8242 acute myeloid leukemia not applicable detail...
IDH2 R140Q Enasidenib acute myeloid leukemia sensitive detail...
IDH2 R172K Enasidenib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Rebastinib acute myeloid leukemia no benefit detail...
NPM1 exon12 Ixazomib acute myeloid leukemia predicted - sensitive detail...
NPM1 exon12 Ixazomib + Vorinostat acute myeloid leukemia sensitive detail...
IDH1 R132H BAY1436032 acute myeloid leukemia sensitive detail...
IDH1 R132L BAY1436032 acute myeloid leukemia sensitive detail...
IDH1 R132C BAY1436032 acute myeloid leukemia sensitive detail...
IDH1 R132S BAY1436032 acute myeloid leukemia sensitive detail...
IDH1 R132G BAY1436032 acute myeloid leukemia sensitive detail...
Unknown unknown SY-1365 + Venetoclax acute myeloid leukemia not applicable detail...
Unknown unknown KPT-8602 acute myeloid leukemia not applicable detail...
Unknown unknown TG02 acute myeloid leukemia not applicable detail...
FLT3 mutant TG02 acute myeloid leukemia sensitive detail...
Unknown unknown Bortezomib + Mivebresib acute myeloid leukemia not applicable detail...
Unknown unknown Azacitidine + Mivebresib acute myeloid leukemia not applicable detail...
Unknown unknown Mivebresib acute myeloid leukemia not applicable detail...
Unknown unknown Mivebresib + Venetoclax acute myeloid leukemia not applicable detail...
IDH2 mutant Enasidenib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Cytarabine + Daunorubicin + Midostaurin acute myeloid leukemia sensitive detail...
KMT2A - MLLT3 I-BET151 + SGC0946 acute myeloid leukemia sensitive detail...
KMT2A - SEPTIN6 I-BET151 + SGC0946 acute myeloid leukemia sensitive detail...
KMT2A - ELL I-BET151 + SGC0946 acute myeloid leukemia sensitive detail...
KMT2A - MLLT10 I-BET151 + SGC0946 acute myeloid leukemia sensitive detail...
KMT2A fusion I-BET151 + SGC0946 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Gilteritinib acute myeloid leukemia sensitive detail...
NPM1 mutant EPZ004777 acute myeloid leukemia predicted - sensitive detail...
NPM1 mutant MI-503 acute myeloid leukemia predicted - sensitive detail...
KMT2A - MLLT3 MI-503 acute myeloid leukemia sensitive detail...
KMT2A - AFF1 MI-503 acute myeloid leukemia sensitive detail...
KMT2A - MLLT1 MI-503 acute myeloid leukemia sensitive detail...
KMT2A - EP300 MI-503 acute myeloid leukemia sensitive detail...
KMT2A fusion MI-503 acute myeloid leukemia predicted - sensitive detail...
Unknown unknown Bortezomib + Tinostamustine acute myeloid leukemia not applicable detail...
Unknown unknown Carfilzomib + Tinostamustine acute myeloid leukemia not applicable detail...
DOT1L V293_L296delinsMM Pinometostat acute myeloid leukemia decreased response detail...
EZH2 T678_R679delinsKK Tazemetostat acute myeloid leukemia resistant detail...
Unknown unknown IACS-010759 acute myeloid leukemia not applicable detail...
KMT2A - MLLT1 NRAS G12D AZD0156 acute myeloid leukemia predicted - sensitive detail...
KMT2A - MLLT1 NRAS G12D AZ20 acute myeloid leukemia predicted - sensitive detail...
Unknown unknown A-485 acute myeloid leukemia not applicable detail...
Unknown unknown GNE-272 acute myeloid leukemia not applicable detail...
Unknown unknown TP-1287 acute myeloid leukemia not applicable detail...
Unknown unknown ST1926-NP acute myeloid leukemia not applicable detail...
Unknown unknown SNS-229 acute myeloid leukemia not applicable detail...
Unknown unknown SNS-510 acute myeloid leukemia not applicable detail...
KIT N822K Avapritinib acute myeloid leukemia sensitive detail...
Unknown unknown GNE-781 acute myeloid leukemia not applicable detail...
FLT3 mutant Selinexor + Sorafenib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Selinexor + Sorafenib acute myeloid leukemia sensitive detail...
FLT3 D835X Selinexor + Sorafenib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 D835X Selinexor + Sorafenib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Azacitidine + Quizartinib acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins Cytarabine + Quizartinib acute myeloid leukemia predicted - sensitive detail...
Unknown unknown Cytarabine + GDC-0575 acute myeloid leukemia not applicable detail...
Unknown unknown Cytarabine + Filgrastim + GDC-0575 acute myeloid leukemia not applicable detail...
SF3B1 K700E H3B-8800 acute myeloid leukemia sensitive detail...
KMT2A - MLLT3 SRSF2 P95H H3B-8800 acute myeloid leukemia sensitive detail...
JAK3 A572V NS-018 acute myeloid leukemia predicted - resistant detail...
CEBPA mutant Ruxolitinib acute myeloid leukemia predicted - sensitive detail...
CEBPA mutant Momelotinib acute myeloid leukemia predicted - sensitive detail...
CEBPA mutant Tofacitinib acute myeloid leukemia predicted - sensitive detail...
CEBPA mutant AZD1480 acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins FLT3 Y842C Sunitinib acute myeloid leukemia resistant detail...
FLT3 exon 14 ins FLT3 Y842C Sorafenib acute myeloid leukemia resistant detail...
FLT3 exon 14 ins FLT3 Y842C AGL2043 acute myeloid leukemia resistant detail...
FLT3 exon 14 ins FLT3 Y842C Lestaurtinib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 Y842C Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 F691L Lestaurtinib acute myeloid leukemia decreased response detail...
FLT3 exon 14 ins FLT3 F691L Midostaurin acute myeloid leukemia decreased response detail...
FLT3 exon 14 ins FLT3 F621L Sunitinib acute myeloid leukemia decreased response detail...
FLT3 exon 14 ins FLT3 F621L AGL2043 acute myeloid leukemia decreased response detail...
FLT3 exon 14 ins FLT3 F621L Sorafenib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 F621L Lestaurtinib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 F621L Midostaurin acute myeloid leukemia sensitive detail...
Unknown unknown AKN-028 + Cytarabine acute myeloid leukemia not applicable detail...
Unknown unknown AKN-028 + Daunorubicin acute myeloid leukemia not applicable detail...
Unknown unknown AKN-028 acute myeloid leukemia not applicable detail...
FLT3 exon 14 ins G-749 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Cytarabine + G-749 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins GTP-14564 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Ki23819 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Semaxanib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins N/A acute myeloid leukemia not applicable detail...
FLT3 exon 14 ins Decitabine + Sorafenib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Azacitidine + Sorafenib acute myeloid leukemia sensitive detail...
Unknown unknown CPX-351 acute myeloid leukemia not applicable detail...
Unknown unknown Cytarabine + Glasdegib acute myeloid leukemia not applicable detail...
Unknown unknown Decitabine + Glasdegib acute myeloid leukemia not applicable detail...
Unknown unknown Cytarabine + Daunorubicin + Glasdegib acute myeloid leukemia not applicable detail...
Unknown unknown Cytarabine + Daunorubicin + Quizartinib acute myeloid leukemia not applicable detail...
FLT3 exon 14 ins Cytarabine + Daunorubicin + Quizartinib acute myeloid leukemia predicted - sensitive detail...
Unknown unknown CPI-613 + Cytarabine + Mitoxantrone acute myeloid leukemia not applicable detail...
Unknown unknown ORY-1001 acute myeloid leukemia not applicable detail...
FLT3 exon 14 ins CG-806 acute myeloid leukemia sensitive detail...
FLT3 wild-type CG-806 acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins FF-10101 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 D835Y FF-10101 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 F691L FF-10101 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 D835H FF-10101 acute myeloid leukemia sensitive detail...
Unknown unknown FF-10501-01 acute myeloid leukemia not applicable detail...
IDH2 R140Q IDH2 Q316E Enasidenib acute myeloid leukemia resistant detail...
IDH2 R140Q IDH2 I319M Enasidenib acute myeloid leukemia resistant detail...
IDH1 R132C IDH1 S280F Ivosidenib acute myeloid leukemia predicted - resistant detail...
Unknown unknown APTO-253 acute myeloid leukemia not applicable detail...
Unknown unknown Flotetuzumab acute myeloid leukemia not applicable detail...
Unknown unknown ABBV-744 acute myeloid leukemia not applicable detail...
FLT3 positive AGS62P1 acute myeloid leukemia predicted - sensitive detail...
Unknown unknown Liposomal Annamycin acute myeloid leukemia not applicable detail...
FLT3 exon 14 ins FLT3 D835F Sorafenib acute myeloid leukemia predicted - resistant detail...
FLT3 exon 14 ins FLT3 D835F Crenolanib acute myeloid leukemia predicted - sensitive detail...
ETV6 - NTRK2 Larotrectinib acute myeloid leukemia sensitive detail...
Unknown unknown Azacitidine + Venetoclax acute myeloid leukemia not applicable detail...
Unknown unknown Decitabine + Venetoclax acute myeloid leukemia not applicable detail...
Unknown unknown Cytarabine + Venetoclax acute myeloid leukemia not applicable detail...
FLT3 mutant Cytarabine + Venetoclax acute myeloid leukemia sensitive detail...
NPM1 mutant Cytarabine + Venetoclax acute myeloid leukemia predicted - sensitive detail...
IDH1 mutant Cytarabine + Venetoclax acute myeloid leukemia sensitive detail...
IDH2 mutant Cytarabine + Venetoclax acute myeloid leukemia sensitive detail...
Unknown unknown Galinpepimut-S acute myeloid leukemia not applicable detail...
Unknown unknown Quizartinib acute myeloid leukemia not applicable detail...
DNMT3A mutant Pinometostat acute myeloid leukemia sensitive detail...
ETV6 - NTRK3 CH7057288 acute myeloid leukemia sensitive detail...
Unknown unknown Azacitidine + Nivolumab acute myeloid leukemia not applicable detail...
KMT2A rearrange KO-539 acute myeloid leukemia predicted - sensitive detail...
DNMT3A mut FLT3 exon 14 ins NPM1 mut KO-539 acute myeloid leukemia predicted - sensitive detail...
DNMT3A wild-type FLT3 mut NPM1 mut KO-539 acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins NPM1 mut Sunitinib acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins KW-2449 acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins NPM1 mut Sorafenib acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins Sorafenib acute myeloid leukemia sensitive detail...
NRAS mutant Pazopanib acute myeloid leukemia predicted - resistant detail...
NRAS mutant Tivozanib acute myeloid leukemia predicted - resistant detail...
NRAS mutant Vemurafenib acute myeloid leukemia predicted - resistant detail...
FLT3 exon 14 ins Entospletinib acute myeloid leukemia predicted - sensitive detail...
NPM1 mutant Entospletinib acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins NPM1 mut Entospletinib acute myeloid leukemia predicted - sensitive detail...
DNMT3A mut NPM1 mut Entospletinib acute myeloid leukemia predicted - sensitive detail...
DNMT3A mut FLT3 exon 14 ins NPM1 mut Entospletinib acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins Ibrutinib acute myeloid leukemia predicted - sensitive detail...
NPM1 mutant Ibrutinib acute myeloid leukemia predicted - sensitive detail...
DNMT3A mut NPM1 mut Ibrutinib acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins NPM1 mut Ibrutinib acute myeloid leukemia predicted - sensitive detail...
DNMT3A mut FLT3 exon 14 ins NPM1 mut Ibrutinib acute myeloid leukemia predicted - sensitive detail...
BCOR mut RUNX1 mut Momelotinib acute myeloid leukemia predicted - sensitive detail...
BCOR mut RUNX1 mut Ruxolitinib acute myeloid leukemia predicted - sensitive detail...
BCOR mut RUNX1 mut Tofacitinib acute myeloid leukemia predicted - sensitive detail...
BCOR mut RUNX1 mut Pyridone 6 acute myeloid leukemia predicted - sensitive detail...
Unknown unknown VS-II-173 acute myeloid leukemia not applicable detail...
Unknown unknown Daunorubicin + VS-II-173 acute myeloid leukemia not applicable detail...
Unknown unknown JSH-150 acute myeloid leukemia not applicable detail...
FLT3 exon 14 ins UNC1666 acute myeloid leukemia sensitive detail...
ASXL1 mutant CG-806 acute myeloid leukemia predicted - sensitive detail...
SRSF2 mutant CG-806 acute myeloid leukemia predicted - sensitive detail...
IDH1 R132X CG-806 acute myeloid leukemia predicted - sensitive detail...
ASXL1 mutant Sunitinib acute myeloid leukemia predicted - resistant detail...
IDH1 R132G Ivosidenib acute myeloid leukemia sensitive detail...
IDH1 R132H Ivosidenib acute myeloid leukemia sensitive detail...
IDH1 R132L Ivosidenib acute myeloid leukemia sensitive detail...
IDH1 R132S Ivosidenib acute myeloid leukemia sensitive detail...
IDH1 mutant LY3410738 acute myeloid leukemia predicted - sensitive detail...
IDH1 mutant Ivosidenib acute myeloid leukemia sensitive detail...
IDH2 R140L Enasidenib acute myeloid leukemia sensitive detail...
IDH2 R140G Enasidenib acute myeloid leukemia sensitive detail...
IDH2 R140W Enasidenib acute myeloid leukemia sensitive detail...
IDH2 R172M Enasidenib acute myeloid leukemia sensitive detail...
IDH2 R172G Enasidenib acute myeloid leukemia sensitive detail...
IDH2 R172S Enasidenib acute myeloid leukemia sensitive detail...
IDH2 R172W Enasidenib acute myeloid leukemia sensitive detail...
FLT3 D835X Cytarabine + Daunorubicin + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 I836X Cytarabine + Daunorubicin + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 D835X Gilteritinib acute myeloid leukemia sensitive detail...
FLT3 I836X Gilteritinib acute myeloid leukemia sensitive detail...
KIT N822K Sunitinib acute myeloid leukemia predicted - sensitive detail...
KIT D816V Crenolanib acute myeloid leukemia sensitive detail...
KIT D816V Midostaurin acute myeloid leukemia sensitive detail...
KIT D816V Avapritinib acute myeloid leukemia sensitive detail...
KIT D816V Sorafenib acute myeloid leukemia resistant detail...
KIT D816V Quizartinib acute myeloid leukemia resistant detail...
KIT D816V Gilteritinib acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins Midostaurin acute myeloid leukemia conflicting detail...
FLT3 exon 14 ins Avapritinib acute myeloid leukemia resistant detail...
RUNX1 - RUNX1T1 KIT N822K Crenolanib acute myeloid leukemia sensitive detail...
RUNX1 - RUNX1T1 KIT N822K Quizartinib acute myeloid leukemia sensitive detail...
RUNX1 - RUNX1T1 KIT N822K Sorafenib acute myeloid leukemia sensitive detail...
RUNX1 - RUNX1T1 KIT N822K Avapritinib acute myeloid leukemia sensitive detail...
RUNX1 - RUNX1T1 KIT N822K Gilteritinib acute myeloid leukemia decreased response detail...
RUNX1 - RUNX1T1 KIT N822K Midostaurin acute myeloid leukemia decreased response detail...
IDH1 mutant Azacitidine acute myeloid leukemia sensitive detail...
IDH2 mutant Azacitidine acute myeloid leukemia sensitive detail...
IDH1 mutant Decitabine acute myeloid leukemia sensitive detail...
IDH2 mutant Decitabine acute myeloid leukemia sensitive detail...
FLT3 wild-type NPM1 mut N/A acute myeloid leukemia not applicable detail...
FLT3 exon 14 ins NPM1 mut N/A acute myeloid leukemia not applicable detail...
FLT3 wild-type NPM1 wild-type N/A acute myeloid leukemia not applicable detail...
FLT3 exon 14 ins NPM1 wild-type N/A acute myeloid leukemia not applicable detail...
ASXL1 mutant N/A acute myeloid leukemia not applicable detail...
DNMT3A R882H NRAS G12D I-BET151 acute myeloid leukemia sensitive detail...
DNMT3A R882H NRAS G12D Trametinib acute myeloid leukemia sensitive detail...
DNMT3A R882H NRAS G12D I-BET151 + Trametinib acute myeloid leukemia sensitive detail...
KIT N822K Imatinib acute myeloid leukemia decreased response detail...
KIT N822K Regorafenib acute myeloid leukemia sensitive detail...
KIT N822K Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon14 Cytarabine + Daunorubicin + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon15 Cytarabine + Daunorubicin + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon16 Cytarabine + Daunorubicin + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon17 Cytarabine + Daunorubicin + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon18 Cytarabine + Daunorubicin + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon19 Cytarabine + Daunorubicin + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon20 Cytarabine + Daunorubicin + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon21 Cytarabine + Daunorubicin + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon22 Cytarabine + Daunorubicin + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon23 Cytarabine + Daunorubicin + Midostaurin acute myeloid leukemia sensitive detail...
KMT2A - MLLT3 N/A acute myeloid leukemia not applicable detail...
FLT3 exon14 Gilteritinib acute myeloid leukemia sensitive detail...
FLT3 exon15 Gilteritinib acute myeloid leukemia sensitive detail...
FLT3 exon16 Gilteritinib acute myeloid leukemia sensitive detail...
FLT3 exon17 Gilteritinib acute myeloid leukemia sensitive detail...
FLT3 exon18 Gilteritinib acute myeloid leukemia sensitive detail...
FLT3 exon19 Gilteritinib acute myeloid leukemia sensitive detail...
FLT3 exon20 Gilteritinib acute myeloid leukemia sensitive detail...
FLT3 exon21 Gilteritinib acute myeloid leukemia sensitive detail...
FLT3 exon22 Gilteritinib acute myeloid leukemia sensitive detail...
FLT3 exon23 Gilteritinib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 LOH Quizartinib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3/CD3 Fabsc antibody acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 LOH FLT3/CD3 Fabsc antibody + Quizartinib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins LAM-003 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 D835Y LAM-003 acute myeloid leukemia sensitive detail...
FLT3 D835Y LAM-003 acute myeloid leukemia predicted - sensitive detail...
FLT3 D835X LAM-003 acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins LAM-003 + Venetoclax acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Daunorubicin + LAM-003 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Cytarabine + LAM-003 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Gilteritinib + LAM-003 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins MK2206 + Venetoclax acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins GSK690693 + Venetoclax acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins A-1210477 + Venetoclax acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Tandutinib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 D835Y Sorafenib acute myeloid leukemia resistant detail...
FLT3 exon 14 ins FLT3 D835Y Tandutinib acute myeloid leukemia resistant detail...
FLT3 exon 14 ins LAM-003 + Tazemetostat acute myeloid leukemia sensitive detail...
Unknown unknown GSK3368715 acute myeloid leukemia not applicable detail...
IDH1 mutant Azacitidine + Venetoclax acute myeloid leukemia sensitive detail...
IDH1 mutant Decitabine + Venetoclax acute myeloid leukemia sensitive detail...
IDH2 mutant Azacitidine + Venetoclax acute myeloid leukemia sensitive detail...
IDH2 mutant Decitabine + Venetoclax acute myeloid leukemia sensitive detail...
FLT3 mutant Decitabine + Venetoclax acute myeloid leukemia sensitive detail...
FLT3 mutant Azacitidine + Venetoclax acute myeloid leukemia sensitive detail...
KMT2A fusion CDKI-73 acute myeloid leukemia sensitive detail...
IDH1 mutant Olaparib acute myeloid leukemia predicted - sensitive detail...
IDH2 mutant Olaparib acute myeloid leukemia predicted - sensitive detail...
IDH1 mutant Talazoparib acute myeloid leukemia predicted - sensitive detail...
IDH2 mutant Talazoparib acute myeloid leukemia predicted - sensitive detail...
IDH1 mutant Daunorubicin + Olaparib acute myeloid leukemia predicted - sensitive detail...
IDH2 mutant Daunorubicin + Olaparib acute myeloid leukemia predicted - sensitive detail...
IDH1 mutant Daunorubicin + Talazoparib acute myeloid leukemia predicted - sensitive detail...
IDH2 mutant Daunorubicin + Talazoparib acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins Sorafenib + Trametinib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins PD-0325901 + Sorafenib acute myeloid leukemia sensitive detail...
NRAS Q61L PD-0325901 acute myeloid leukemia predicted - sensitive detail...
NRAS Q61L PD-0325901 + Sorafenib acute myeloid leukemia no benefit detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00084695 Phase II Fludarabine Busulfan + Melphalan anti-thymocyte globulin Cyclophosphamide Prednisone Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases Unknown status
NCT00513474 Phase I Rasburicase Methotrexate Sirolimus Cyclosporine Tacrolimus Filgrastim Busulfan + Cyclophosphamide + Etoposide Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant Completed
NCT00679536 Phase Ib/II anti-thymocyte globulin + Busulfan + Fludarabine Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors Unknown status
NCT00801489 Phase II Cytarabine + Filgrastim + Fludarabine + Gemtuzumab ozogamicin Cytarabine + Filgrastim + Fludarabine + Gemtuzumab ozogamicin + Idarubicin Fludarabine, Cytarabine, Filgrastim, Gemtuzumab Ozogamicin, and Idarubicin in Core Binding Factor (CBF) Leukemias Recruiting
NCT00857389 Phase II Cyclophosphamide Filgrastim Tacrolimus Thiotepa anti-thymocyte globulin + Busulfan + Clofarabine Methotrexate Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies Completed
NCT00866281 Phase Ib/II Midostaurin A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia Terminated
NCT00887068 Phase III Azacitidine Randomized Allogeneic Azacitidine Study Completed
NCT00892190 Phase I Dasatinib Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome Completed
NCT00908167 Phase I Clofarabine + Cytarabine + Sorafenib Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies Completed
NCT00946647 Phase II Panobinostat Azacitidine A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). Completed
NCT01084252 Phase Ib/II Isatuximab Dexamethasone + Isatuximab Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies Active, not recruiting
NCT01093573 Phase Ib/II Azacitidine + Midostaurin Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia Unknown status
NCT01187810 Phase I Fenretinide Cytarabine Methotrexate Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL Completed
NCT01211457 Phase Ib/II sapacitabine + Venetoclax Decitabine + sapacitabine Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes Recruiting
NCT01222143 Phase Ib/II Cytarabine + Etoposide + Mitoxantrone Nilotinib Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia Terminated
NCT01251575 Phase II Fludarabine Cyclosporine + Mycophenolate mofetil + Sirolimus Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant Completed
NCT01252667 Phase II Cyclosporine + Mycophenolate mofetil Clofarabine Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant Active, not recruiting
NCT01266083 Phase II WT1 vaccine Trial of a WT-1 Analog Peptide Vaccine in Patients With Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) Completed
NCT01303796 Phase III Decitabine + sapacitabine Decitabine A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (SEAMLESS) Completed
NCT01321346 Phase I Cytarabine Panobinostat A Study Of Panobinostat In Children With Refractory Hematologic Malignancies Completed
NCT01338987 Phase II Tacrolimus Methotrexate Leuprolide Cyclophosphamide Pilot Study of Lupron to Improve Immune Function After Allogeneic Bone Marrow Transplantation Active, not recruiting
NCT01352650 Phase I Decitabine + Plerixafor Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML) Completed
NCT01371981 Phase III Cytarabine + Daunorubicin + Etoposide Sorafenib Cytarabine + Etoposide Cytarabine + Mitoxantrone Asparaginase + Cytarabine Bortezomib Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting
NCT01398462 Phase I CWP232291 Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients Completed
NCT01449058 Phase Ib/II Alpelisib + Binimetinib A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors Completed
NCT01463046 Phase I Cytarabine + Daunorubicin + Panobinostat Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome Completed
NCT01483274 Phase I Decitabine Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation Withdrawn
NCT01498445 Phase Ib/II Dasatinib + Decitabine An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357) Active, not recruiting
NCT01515527 Phase II Cytarabine Cladribine Decitabine Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) Recruiting
NCT01534260 Phase Ib/II Bortezomib + Sorafenib + Vorinostat Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype Completed
NCT01546038 Phase Ib/II Glasdegib Cytarabine Decitabine Cytarabine + Daunorubicin A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed
NCT01578109 Phase I Sorafenib Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia Active, not recruiting
NCT01606579 Phase Ib/II Cytarabine + Pri-724 Dasatinib + Pri-724 Pri-724 Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies Completed
NCT01620216 Phase II Sunitinib Dasatinib Nilotinib Ponatinib Sorafenib Validation of an in Vitro Assay to Predict Targeted Therapies for Acute Leukemia Patients Recruiting
NCT01621477 Phase II Plerixafor Tacrolimus Mycophenolate mofetil anti-thymocyte globulin + Busulfan + Clofarabine Cyclophosphamide + Cytarabine T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant Terminated
NCT01621542 Phase I WT2725 Clinical Study of WT2725 in Patients With Advanced Malignancies Completed
NCT01627041 Phase II Cytarabine + Daunorubicin + Decitabine Cytarabine + Daunorubicin Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia Active, not recruiting
NCT01634217 Phase I Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation Completed
NCT01640301 Phase Ib/II Aldesleukin WT1 sensitized T cells Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant Active, not recruiting
NCT01657682 Phase II Crenolanib A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations Completed
NCT01685411 Phase 0 Busulfan + Cyclophosphamide Filgrastim Allopurinol Mycophenolate mofetil anti-thymocyte globulin Tacrolimus Levetiracetam Busulfan and Cyclophosphamide Followed By ALLO BMT Recruiting
NCT01687400 Phase II Decitabine Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed
NCT01707004 Phase I Cyclophosphamide Decitabine Filgrastim Fludarabine Busulfan Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed
NCT01729845 Phase Ib/II Cytarabine + Etoposide + Mitoxantrone Decitabine Decitabine Followed By Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Completed
NCT01736943 Phase II Bortezomib + Pegylated liposomal-doxorubicin Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia Active, not recruiting
NCT01744223 Phase Ib/II Rimiducid BPX-501 Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant Active, not recruiting
NCT01746849 Phase II Leuprolide Cyclophosphamide Thiotepa Palifermin Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Recruiting
NCT01773395 Phase II Busulfan + Fludarabine + Methotrexate + Tacrolimus Busulfan + Fludarabine + GVAX + Methotrexate + Tacrolimus GVAX vs. Placebo for MDS/AML After Allo HSCT Recruiting
NCT01786343 Phase II Decitabine Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML) Completed
NCT01794702 Phase Ib/II Idarubicin Clofarabine Cytarabine Decitabine Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia Completed
NCT01798901 Phase I AR-42 + Decitabine AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia Completed
NCT01804101 Phase I CPX-351 Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia Completed
NCT01806571 Phase II Cytarabine + Daunorubicin Nilotinib Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting
NCT01814826 Phase I MLN4924 Azacitidine Study of MLN4924 Plus Azacitidine in Treatment-Naïve Patients With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older Completed
NCT01822015 Phase I Cytarabine + Idarubicin + Sirolimus Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed
NCT01823198 Phase Ib/II Methotrexate anti-thymocyte globulin + Busulfan + Fludarabine Tacrolimus Filgrastim Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies Recruiting
NCT01829503 Phase II Cytarabine + Decitabine Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) Completed
NCT01834248 Phase I DEC-205-NY-ESO-1 fusion protein vaccine + Decitabine DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Completed
NCT01835288 Phase II Arsenic trioxide Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Withdrawn
NCT01838395 Phase II BKT140 + Cytarabine Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients Completed
NCT01841333 Phase II Glasdegib PF-04449913 For Patients With Acute Leukemia at High Risk of Relapse After Donor Stem Cell Transplant Active, not recruiting
NCT01842646 Phase II Glasdegib Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS) Active, not recruiting
NCT01846624 Phase II Decitabine + Midostaurin Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Terminated
NCT01849276 Phase I Cytarabine + Metformin Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML Terminated
NCT01861314 Phase I Bortezomib + Decitabine + Sorafenib Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia Active, not recruiting
NCT01869114 Phase II Azacitidine + Sirolimus Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy Active, not recruiting
NCT01869803 Phase I Gemtuzumab ozogamicin Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia Approved for marketing
NCT01870596 Phase II Cytarabine MK-8776 Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia Completed
NCT01876953 Phase Ib/II Cytarabine + Dasatinib + Idarubicin Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia Completed
NCT01880437 Phase II Cytarabine + Vismodegib A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myleodysplastic Syndrome Terminated
NCT01883362 Phase II Midostaurin Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML Completed
NCT01885689 Phase II Clofarabine + Melphalan Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia or Acute Leukemia in Remission Active, not recruiting
NCT01885897 Phase Ib/II ALT-803 IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT Active, not recruiting
NCT01892371 Phase Ib/II Azacitidine + Quizartinib Cytarabine + Quizartinib Quizartinib With Azacitidine or Cytarabine in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Active, not recruiting
NCT01893320 Phase Ib/II Decitabine + Vosaroxin Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome Active, not recruiting
NCT01898793 Phase Ib/II Aldesleukin + Cyclophosphamide + Fludarabine ALT-803 + Cyclophosphamide + Fludarabine Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Recruiting
NCT01907815 Phase II Trametinib + Uprosertib Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia Terminated
NCT01926587 Phase Ib/II Azacitidine + Regorafenib Oral Rigosertib in Combination With Azacitidine Active, not recruiting
NCT01943682 Phase I CPX-351 Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma Completed
NCT01961765 Phase I Cabozantinib Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed
NCT02003573 Phase I Decitabine + Volasertib Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML) Terminated
NCT02010645 Phase II Decitabine + Eltrombopag Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS) Terminated
NCT02016729 Phase I Trametinib KRT-232 A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia Completed
NCT02019069 Phase II CPX-351 CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed
NCT02029417 Phase II Cytarabine + Decitabine + Omacetaxine mepesuccinate Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Terminated
NCT02039726 Phase III Filgrastim Cytarabine + Fludarabine + Idarubicin Cytarabine + Etoposide + Mitoxantrone Quizartinib An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Active, not recruiting
NCT02046122 Phase I Cytarabine + Idarubicin Adoptive Transfer of Haplo-identical DLI for AML and MDS Active, not recruiting
NCT02049801 Phase I Binimetinib + Cytarabine + Idarubicin MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Terminated
NCT02057770 Phase I Busulfan + Cyclophosphamide + Fludarabine Tocilizumab Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Terminated
NCT02071927 Phase I CB-839 Study of the Glutaminase Inhibitor CB-839 in Leukemia Completed
NCT02073838 Phase II Decitabine Ribavirin + Vismodegib Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML Unknown status
NCT02078609 Phase I LGH447 A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS) Completed
NCT02083250 Phase I anti-thymocyte globulin Vorinostat Busulfan + Clofarabine + Fludarabine Fludarabine/Clofarabine/Busulfan Combined With SAHA in Acute Leukemia Active, not recruiting
NCT02085408 Phase III Clofarabine Cytarabine + Daunorubicin Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting
NCT02088541 Phase II Cytarabine Azacitidine Decitabine Selinexor Hydroxyurea Selinexor (KPT-330) in Older Patients With Relapsed AML Completed
NCT02089230 Phase Ib/II Binimetinib MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy Completed
NCT02091245 Phase I Selinexor Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML Active, not recruiting
NCT02093403 Phase I Decitabine + Selinexor Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed
NCT02096055 Phase II Cladribine Guadecitabine Idarubicin 4-Arm Phase II Study of SGI-110 in Elderly Acute Myeloid Leukemia (AML) Active, not recruiting
NCT02098967 Phase I RO6839921 A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia. Completed
NCT02109627 Phase I Cytarabine + Ficlatuzumab Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML Terminated
NCT02109744 Phase Ib/II Decitabine + Sirolimus Decitabine + Ribavirin Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients Recruiting
NCT02115295 Phase II Cladribine + Cytarabine + Idarubicin Midostaurin Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With Acute Myeloid Leukemia (AML), High Risk Myelodysplastic Syndrome (HR MDS) or Myeloid Blast Phase of Chronic Myeloid Leukemia (CML) Recruiting
NCT02117297 Phase II Gemtuzumab ozogamicin SCT Plus Immune Therapy in Average Risk AML/MDS Recruiting
NCT02121418 Phase I Cytarabine + Decitabine Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm Completed
NCT02126553 Phase II Lenalidomide Lenalidomide Maintenance With High Risk (HR) Acute Myeloid Leukemia (AML) in Remission Recruiting
NCT02141477 Phase II Decitabine + Omacetaxine mepesuccinate Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Terminated
NCT02141828 Phase I Pinometostat A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene Completed
NCT02143635 Phase I HDM201 Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt Active, not recruiting
NCT02152956 Phase Ib/II Flotetuzumab Safety Study of MGD006 in Relapsed/Refractory Acute Myeloid Leukemia (AML) or Intermediate-2/High Risk MDS Recruiting
NCT02159495 Phase I Cyclophosphamide Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Recruiting
NCT02177812 Phase I GSK2879552 A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML) Terminated
NCT02181478 Phase I Fludarabine Cyclophosphamide Intra-Osseous Co-Transplant of UCB and hMSC Active, not recruiting
NCT02190695 Phase II Carboplatin + Decitabine Arsenic trioxide + Decitabine A Safety and Efficacy Study Using Decitabine, Decitabine/Carboplatin, Decitabine/Arsenic for the Treatment of Relapsed, Refractory, and Elderly Acute Myeloid Leukemia , Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Unknown status
NCT02193958 Phase Ib/II FF-10501-01 Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies Completed
NCT02196857 Phase II Azacitidine + Sorafenib Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation Completed
NCT02200380 Phase II Plerixafor CDX-301 A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs Terminated
NCT02203773 Phase I Decitabine + Venetoclax Azacitidine + Venetoclax Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo) Active, not recruiting
NCT02203903 Phase I MultiTAA-specific T cells Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies (RESOLVE) Recruiting
NCT02204020 Phase II Azacitidine Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS Withdrawn
NCT02204085 Phase Ib/II GO-203-2C A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia Active, not recruiting
NCT02212561 Phase Ib/II Selinexor Cytarabine Cytarabine + Dexamethasone + Methotrexate Fludarabine Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome Completed
NCT02221310 Phase II Busulfan + Cyclophosphamide + Gemtuzumab ozogamicin Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS Recruiting
NCT02236013 Phase I Cytarabine + Idarubicin Gilteritinib A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Recruiting
NCT02238522 Phase I Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML Withdrawn
NCT02250937 Phase II Cladribine Busulfan Busulfan + Venetoclax Fludarabine Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Recruiting
NCT02257138 Phase Ib/II Decitabine + Ruxolitinib Study of Ruxolitinib Plus Decitabine in Patients With Acute Myeloid Leukemia (AML) Recruiting
NCT02267863 Phase I APTO-253 A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS Recruiting
NCT02269579 Phase II CPX-351 Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment Withdrawn
NCT02270463 Phase Ib/II tagraxofusp-erzs SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission Active, not recruiting
NCT02270788 Phase I Cytarabine + Leucovorin + Methotrexate Crenolanib + Sorafenib Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies Completed
NCT02273102 Phase I Tranylcypromine + Tretinoin Phase 1 Study of TCP-ATRA for Adult Patients With AML and MDS (TCP-ATRA) Active, not recruiting
NCT02275533 Phase II Nivolumab Nivolumab in Eliminating Minimal Residual Disease and Preventing Relapse in Patients With Acute Myeloid Leukemia in Remission After Chemotherapy Active, not recruiting
NCT02283177 Phase II Crenolanib + Cytarabine + Daunorubicin A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations Active, not recruiting
NCT02286726 Phase II CPX-351 CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia Completed
NCT02287233 Phase I Cytarabine + Venetoclax A Study Evaluating ABT-199 in Combination With Low-Dose Cytarabine in Treatment-Naïve Subjects With Acute Myelogenous Leukemia (AML) Active, not recruiting
NCT02296242 Phase Ib/II Ulixertinib Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes Completed
NCT02299518 Phase I Etoposide Selinexor Cytarabine + Etoposide + Mitoxantrone Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed
NCT02305563 Phase Ib/II Cytarabine + Ulocuplumab An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia Terminated
NCT02306291 Phase Ib/II Cytarabine + Idarubicin Cytarabine + Etoposide + Mitoxantrone Uproleselan Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML Completed
NCT02308761 Phase I TEN-010 A Dose Escalation and Cohort Expansion Study of TEN-010 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome Completed
NCT02312102 Phase I Bortezomib + Lenalidomide Phase I Study of Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation Active, not recruiting
NCT02319369 Phase I DS-3032b Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-3032b in Hematological Malignancies Recruiting
NCT02323113 Phase Ib/II TAK-659 Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML) Completed
NCT02323607 Phase I Cytarabine + Daunorubicin + Pacritinib Decitabine + Pacritinib Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations Completed
NCT02333162 Phase I Mycophenolate mofetil Tacrolimus Fludarabine + Melphalan Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant Recruiting
NCT02335814 Phase I FLX925 First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia Terminated
NCT02343939 Phase Ib/II Decitabine Cytarabine + Daunorubicin Entospletinib Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML) Terminated
NCT02348489 Phase III Guadecitabine Cytarabine Azacitidine Decitabine SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction Completed
NCT02351037 Phase II Ibrutinib Cytarabine A Multicenter Open-Label Phase 2a Study of Ibrutinib With or Without Cytarabine in Subjects With Acute Myeloid Leukemia Terminated
NCT02356159 Phase Ib/II Cytarabine + Fludarabine Palifermin Prednisone Filgrastim Methotrexate + Sirolimus + Tacrolimus Doxorubicin + Etoposide + Fludarabine + Vincristine Cyclophosphamide + Fludarabine Rituximab Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Recruiting
NCT02367456 Phase Ib/II Azacitidine + Glasdegib A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In 1st Line MDS, AML and CMML Patients Active, not recruiting
NCT02381548 Phase I Adavosertib + Belinostat Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia Terminated
NCT02391480 Phase I Mivebresib A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer Completed
NCT02397720 Phase II Azacitidine + Nivolumab A Study of Nivolumab (BMS-936558) in Combination With 5-azacytidine (Vidaza) for the Treatment of Patients With Refractory/ Relapsed Acute Myeloid Leukemia Recruiting
NCT02400255 Phase II Crenolanib Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients Recruiting
NCT02400281 Phase Ib/II Azacitidine Crenolanib Cytarabine + Idarubicin Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients Active, not recruiting
NCT02403310 Phase I Cytarabine + Daunorubicin Selinexor A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML Active, not recruiting
NCT02412475 Phase I Cytarabine Sorafenib Vorinostat Filgrastim Daunorubicin Fludarabine Decitabine Epigenetic Reprogramming in Relapse AML Terminated
NCT02416908 Phase Ib/II Selinexor Cladribine + Cytarabine + Plerixafor Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia Completed
NCT02418000 Phase Ib/II E6201 A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 Mutation Terminated
NCT02421939 Phase III Cytarabine Cytarabine + Fludarabine + Idarubicin Cytarabine + Etoposide + Mitoxantrone Azacitidine Gilteritinib Filgrastim A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation Active, not recruiting
NCT02464657 Phase Ib/II Dexamethasone Cytarabine + Idarubicin + Nivolumab Nivolumab in Acute Myeloid Leukemia (AML) Active, not recruiting
NCT02472145 Phase III Decitabine Decitabine + Talacotuzumab An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Completed
NCT02485535 Phase I Selinexor Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant Active, not recruiting
NCT02487459 Phase I BPX-501 Rimiducid Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies Withdrawn
NCT02488408 Phase I Cytarabine BGB-324 Multicenter Open-label Study of BGB324 as a Single Agent and in Combination With Cytarabine in Patients With AML Unknown status
NCT02494167 Phase I MultiTAA-specific T cells Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) Recruiting
NCT02498665 Phase I DSP-7888 A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies Completed
NCT02520011 Phase II Alvocidib Cytarabine + Mitoxantrone Alvocidib Biomarker-driven Phase 2 AML Study Recruiting
NCT02520427 Phase I AMG 330 A Phase 1 Study of AMG 330 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia Recruiting
NCT02521493 Phase III Etoposide Thioguanine Cytarabine Asparaginase Erwinia chrysanthemi mitoxantrone hydrochloride Daunorubicin Asparaginase Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome Recruiting
NCT02527174 Phase I Cytarabine + Idarubicin + Volasertib A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia (VIAC) Withdrawn
NCT02528877 Phase I Fludarabine + Melphalan Ruxolitinib + Sirolimus + Tacrolimus Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis Withdrawn
NCT02530034 Phase I Hu8F4 Hu8F4 in Treating Patients With Advanced Hematologic Malignancies Recruiting
NCT02530476 Phase Ib/II Selinexor + Sorafenib Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia Completed
NCT02532010 Phase II Decitabine + Pacritinib Cytarabine + Pacritinib Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML Terminated
NCT02532231 Phase II Nivolumab Nivolumab in Acute Myeloid Leukemia (AML) in Remission at High Risk for Relapse Recruiting
NCT02533115 Expanded access CPX-351 EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML Approved for marketing
NCT02543879 Phase I FT-1101 Azacitidine + FT-1101 Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies Completed
NCT02545283 Phase III Cytarabine Cytarabine + Idasanutlin A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Patients With Relapsed or Refractory Acute Myeloid Leukemia Active, not recruiting
NCT02560025 Phase II Alisertib Daunorubicin Idarubicin Cytarabine Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML Active, not recruiting
NCT02561455 Phase Ib/II Gilteritinib Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial Active, not recruiting
NCT02573363 Phase I Cytarabine Mitoxantrone Selinexor Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia Active, not recruiting
NCT02576301 Phase Ib/II OXi4503 Cytarabine + OXi4503 Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS Recruiting
NCT02577406 Phase III Azacitidine Cytarabine Enasidenib An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation (IDHENTIFY) Active, not recruiting
NCT02582359 Cytarabine Daunorubicin MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age Recruiting
NCT02583893 Phase II Cytarabine + Etoposide + Mitoxantrone + Sirolimus Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia Recruiting
NCT02610777 Phase II Azacitidine MLN4924 An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML) Active, not recruiting
NCT02624570 Phase I Midostaurin Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy. Available
NCT02626338 Phase Ib/II Crenolanib + Cytarabine + Mitoxantrone Pilot Study of Crenolanib Combined With Cytarabine and Mitoxantrone in Subjects With R/R AML Completed
NCT02632708 Phase I Enasidenib + Etoposide + Mitoxantrone Cytarabine + Enasidenib Cytarabine + Idarubicin + Ivosidenib Cytarabine + Daunorubicin + Enasidenib Cytarabine + Enasidenib + Idarubicin Etoposide + Ivosidenib + Mitoxantrone Cytarabine + Ivosidenib Cytarabine + Daunorubicin + Ivosidenib Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation Active, not recruiting
NCT02632721 Phase II BI 836858 + Decitabine Decitabine A Study to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML) Active, not recruiting
NCT02634827 Phase II Decitabine + Midostaurin Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation Terminated
NCT02635074 Phase I Cytarabine + Ibrutinib + Idarubicin Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Terminated
NCT02641002 Phase I CC-90002 A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS) Terminated
NCT02642965 Phase Ib/II CPX-351 + Cytarabine + Filgrastim + Fludarabine Liposomal Cytarabine-Daunorubicin CPX-351, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia Active, not recruiting
NCT02649764 Phase I Cytarabine + Fludarabine + Prexasertib LY2606368 in Combination With Cytarabine and Fludarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HRMDS) Active, not recruiting
NCT02652871 Phase I Cytarabine + Idarubicin + LY2510924 A Phase 1b, Open-label Study of LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed
NCT02665065 Phase III Fludarabine + Iomab-B Study of Iomab-B Prior to HCT vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory AML (SIERRA) Recruiting
NCT02665143 Phase Ib/II Cytarabine + Idarubicin Nintedanib A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia Recruiting
NCT02666950 Phase II Adavosertib Cytarabine WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed
NCT02668653 Phase III Cytarabine + Daunorubicin + Idarubicin Quizartinib Quizartinib With Standard of Care Chemotherapy and as Maintenance Therapy in Patients With Newly Diagnosed FLT3-ITD (+) AML Active, not recruiting
NCT02670044 Phase Ib/II Cobimetinib + Venetoclax RO5503781 + Venetoclax A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy Recruiting
NCT02674763 Phase I IMGN779 Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia Completed
NCT02676323 Phase Ib/II Cytarabine + Fludarabine + Leucovorin + Panobinostat Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome Terminated
NCT02677922 Phase Ib/II Azacitidine + Ivosidenib Azacitidine Azacitidine + Enasidenib A Safety and Efficacy Study of Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus Subcutaneous Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) Active, not recruiting
NCT02680951 Phase I Cytarabine + Dasatinib + Fludarabine + Idarubicin Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia Withdrawn
NCT02683395 Phase I PLX51107 A Study of PLX51107 in Advanced Malignancies Terminated
NCT02684162 Phase II Guadecitabine SGI-110 With Donor Lymphocyte Infusion (DLI) for Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing Post Allogeneic Stem Cell Transplantation (AlloSCT) Recruiting
NCT02698189 Phase I Birabresib A Dose Exploration Study With MK-8628 in Participants With Selected Hematologic Malignancies (MK-8628-005) Active, not recruiting
NCT02708641 Phase II Pembrolizumab A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients 60 With AML Recruiting
NCT02719574 Phase I FT-2102 Azacitidine + FT-2102 Dose-Escalation Study of FT-2102 as a Single Agent and in Combination With Azacitidine in Patients With AML or MDS With an IDH1 Mutation Recruiting
NCT02721875 Phase I Azacitidine Volasertib Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes Terminated
NCT02723435 Phase II Midostaurin Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant Withdrawn
NCT02727803 Phase II anti-thymocyte globulin + Fludarabine + haNK cells + Melphalan anti-thymocyte globulin + Cyclophosphamide + Fludarabine + haNK cells + Rituximab anti-thymocyte globulin + Busulfan + Clofarabine + Fludarabine + haNK cells Personalized NK Cell Therapy After Chemotherapy and Cord Blood Transplant in Treating Patients With Myelodysplastic Syndrome, Leukemia, Lymphoma or Multiple Myeloma Recruiting
NCT02728050 Phase Ib/II Sorafenib Cladribine + Cytarabine + Filgrastim + Mitoxantrone Filgrastim, Cladribine, Cytarabine and Mitoxantrone With or Without Sorafenib Tosylate in Treating Patients With Newly-Diagnosed, High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome Recruiting
NCT02743611 Phase I Rimiducid BPX-701 Dose Finding Study Evaluating Safety and Feasibility in Patients With Relapsed or Refractory Myeloid Neoplasms Active, not recruiting
NCT02749708 Phase Ib/II IRX5183 Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome Terminated
NCT02752035 Phase II Gilteritinib Azacitidine + Gilteritinib Azacitidine A Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation in Patients Not Eligible for Intensive Induction Chemotherapy Recruiting
NCT02756572 Phase I Sirolimus Mycophenolate mofetil Cyclosporine Cytarabine Melphalan Cladribine Filgrastim mitoxantrone hydrochloride Fludarabine Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myelodysplastic Syndrome or Acute Myeloid Leukemia Active, not recruiting
NCT02756962 Phase II Midostaurin Cytarabine Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance Recruiting
NCT02768792 Phase II Pembrolizumab High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML Active, not recruiting
NCT02771197 Phase II Fludarabine + Melphalan Pembrolizumab Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant Recruiting
NCT02775903 Phase II Azacitidine Azacitidine + Durvalumab An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Subjects With Acute Myeloid Leukemia (AML) Active, not recruiting
NCT02779283 Phase I Dasatinib Nilotinib Ponatinib Sorafenib Cytarabine + Idarubicin Sunitinib Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Recruiting
NCT02781883 Phase II BP1001 + Cytarabine Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With LDAC in Patients With Previously Untreated AML Recruiting
NCT02782546 Phase II Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation Recruiting
NCT02790515 Phase II Sirolimus anti-thymocyte globulin Blinatumomab Tacrolimus Thiotepa Melphalan Fludarabine Cyclophosphamide Mesna Rituximab Filgrastim Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation Recruiting
NCT02791919 Phase I Adavosertib Cytarabine + Filgrastim + Fludarabine Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia Withdrawn
NCT02793544 Phase II Cyclophosphamide Busulfan Sirolimus Mycophenolate mofetil Mesna Fludarabine HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide Active, not recruiting
NCT02795520 Phase Ib/II OTS167 Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia Recruiting
NCT02802267 Phase II Decitabine + Inecalcitol Decitabine Efficacy Study of Inecalcitol With Decitabine in Acute Myeloid Leukemia Patients Unfit for Standard Chemotherapy Unknown status
NCT02807558 Phase II Azacitidine + Tamibarotene Tamibarotene A Biomarker-Directed Phase 2 Trial of SY-1425 in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Recruiting
NCT02829840 Phase Ib/II Azacitidine + Ponatinib Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML) Withdrawn
NCT02835222 Phase II Cytarabine + Daunorubicin + Selinexor Selinexor With Induction, Consolidation, and Maintenance Therapy in Treating Older Patients With Acute Myeloid Leukemia Recruiting
NCT02835729 Phase Ib/II Cytarabine + Idarubicin Cytarabine + Idarubicin + Indoximod A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Recruiting
NCT02841540 Phase I H3B-8800 A Phase 1 Study to Evaluate H3B-8800 in Participants With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Active, not recruiting
NCT02845297 Phase II Azacitidine + Pembrolizumab Phase 2 Study of Azacitidine in Combination With Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients and in Newly Diagnosed Older (?65 Years) AML Patients Recruiting
NCT02846376 Phase I Ipilimumab Ipilimumab + Nivolumab Nivolumab Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant (CPIT-002) Recruiting
NCT02848001 Phase I CC-90009 A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes Recruiting
NCT02848248 Phase I SGN-CD123A A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia Terminated
NCT02864290 Phase I AGS62P1 A Study to Evaluate Escalating Doses of AGS62P1 Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML) Recruiting
NCT02878785 Phase Ib/II Decitabine + Talazoparib Decitabine and Talazoparib in Untreated AML and R/R AML (1565GCC) Recruiting
NCT02882321 Phase I IACS-010759 Study of IACS-010759 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) Active, not recruiting
NCT02890329 Phase I Decitabine + Ipilimumab Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia Recruiting
NCT02890758 Phase I ALT-803 Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 Recruiting
NCT02892318 Phase I Atezolizumab + Guadecitabine A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML) Completed
NCT02905994 Phase I Cytarabine + Idarubicin + Volasertib Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia Withdrawn
NCT02909972 Phase I ALRN-6924 + Cytarabine ALRN-6924 Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome Completed
NCT02920008 Phase III Decitabine Azacitidine Cytarabine Guadecitabine Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia Active, not recruiting
NCT02927262 Phase III Gilteritinib A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission Active, not recruiting
NCT02930109 Phase Ib/II Cytarabine + Triciribine A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia Recruiting
NCT02931110 Phase I CBL0137 Study of IV CBL0137 in Previously Treated Hematological Subjects Unknown status
NCT02936752 Phase I Entinostat + Pembrolizumab Entinostat and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome After DNMTi Therapy Failure Recruiting
NCT02953561 Phase Ib/II Avelumab + Azacitidine Avelumab (antiPDL1) and Azacytidine in Acute Myeloid Leukemia (AML) Terminated
NCT02954653 Phase I PF-06747143 Cytarabine + Daunorubicin + PF-06747143 Azacitidine + Decitabine + PF-06747143 A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia Terminated
NCT02979366 Phase I MIK665 Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome Active, not recruiting
NCT02981914 Phase 0 Pembrolizumab Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation Recruiting
NCT02989844 Phase II ALT-803 QUILT-3.035: Relapse Prophylaxis With ALT-803 for AML and MDS Pts Following Allo HSCT Suspended
NCT02993523 Phase III Azacitidine + Venetoclax Azacitidine A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Elderly Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy Active, not recruiting
NCT02996474 Phase Ib/II Decitabine + Pembrolizumab Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia Completed
NCT02997202 Gilteritinib A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML) Recruiting
NCT03008187 Phase Ib/II SEL24-B489 SEL24 in Patients With AML Recruiting
NCT03009240 Phase I Decitabine + MLN4924 Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia Recruiting
NCT03013998 Phase Ib/II Azacitidine + Enasidenib Azacitidine + Entospletinib Cytarabine + Daunorubicin + Samalizumab Azacitidine + BI 836858 Study of Biomarker-Based Treatment of Acute Myeloid Leukemia Recruiting
NCT03017820 Phase I VSV-hIFNbeta-NIS VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma Recruiting
NCT03018405 Phase I NKR-2 cells A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK) Recruiting
NCT03041688 Phase I Decitabine + KRT-232 MDM2 Inhibitor AMG-232 and Decitabine in Treating Patients With Relapsed, Refractory, or Newly-Diagnosed Acute Myeloid Leukemia Recruiting
NCT03042689 Phase I Regorafenib Study of Regorafenib in Patients With Advanced Myeloid Malignancies Recruiting
NCT03050216 Phase II ALT-803 + Cyclophosphamide + Fludarabine Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML Active, not recruiting
NCT03055286 Phase Ib/II CWP232291 + Cytarabine Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients Active, not recruiting
NCT03059485 Phase II DC/AML Vaccine DC/AML Vaccine + Durvalumab DC/AML Fusion Cell Vaccine vs DC/AML Fusion Cell Vaccine Plus Durvalumab vs Observation in Patients Who Achieve a Chemotherapy-induced Remission Recruiting
NCT03063203 Phase II Decitabine Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia Recruiting
NCT03063944 Phase I Decitabine + OPB-111077 STAT Inhibitor OPB-111077 and Decitabine in Treating Patients With Acute Myeloid Leukemia That Is Refractory or Newly Diagnosed and Ineligible for Intensive Chemotherapy Recruiting
NCT03066648 Phase I Decitabine + Spartalizumab Decitabine + MBG453 + Spartalizumab Decitabine + MBG453 Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS Recruiting
NCT03069352 Phase III Cytarabine + Venetoclax Cytarabine A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naïve Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy Active, not recruiting
NCT03069469 Phase I DCC-3014 Study of DCC-3014 in Patients With Advanced Malignancies Recruiting
NCT03070093 Expanded access Gilteritinib Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD) Approved for marketing
NCT03071276 Phase II Cytarabine + Fludarabine + Methotrexate + Prednisone + Selinexor Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia Terminated
NCT03072043 Phase Ib/II APR-246 + Azacitidine Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms Active, not recruiting
NCT03081780 Phase I FATE-NK100 Open Label NK Cell Infusion (FATE-NK100) With Subq IL-2 in Adults With AML Active, not recruiting
NCT03082209 Phase I ABBV-621 A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously Treated Solid Tumors and Hematologic Malignancies Recruiting
NCT03092674 Phase II Cytarabine + Decitabine Azacitidine + Midostaurin Azacitidine + Nivolumab Azacitidine Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Suspended
NCT03106428 Phase I MEDI7247 A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies Completed
NCT03110354 Phase I DS-3201b DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL) Recruiting
NCT03113643 Phase I Azacitidine + tagraxofusp-erzs + Venetoclax Azacitidine + tagraxofusp-erzs SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) Recruiting
NCT03114228 Expanded access Midostaurin An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML) No longer available
NCT03125239 Phase I LY2874455 + Merestinib Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia Recruiting
NCT03127735 Phase I BAY1436032 BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML) Completed
NCT03128034 Phase Ib/II Cyclosporine + Fludarabine + Mycophenolate mofetil + Sirolimus 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome Recruiting
NCT03132454 Phase I Decitabine + Palbociclib Dexamethasone + Palbociclib Palbociclib Palbociclib + Sorafenib Study of Palbociclib Alone and in Combination in Patients With Relapsed and Refractory (R/R) Leukemias Recruiting
NCT03144245 Phase I AMV-564 Study of AMV564 in Patients With AML Recruiting
NCT03151408 Phase III Azacitidine Azacitidine + Pracinostat An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia Recruiting
NCT03154827 Phase Ib/II Atezolizumab + BKT140 A Phase Ib/II, Multicenter, Single Arm, Open-Label Study, To Evaluate the Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab Combination for Maintenance Treatment in Subjects With Acute Myeloid Leukemia Who Are 60 Years or Older - The BATTLE Study Recruiting
NCT03164057 Phase II Etoposide Filgrastim Dexrazoxane Daunorubicin Idarubicin Fludarabine Asparaginase Cytarabine Sorafenib Mitoxantrone Decitabine Azacitidine A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia Recruiting
NCT03173248 Phase III Azacitidine + Ivosidenib Ivosidenib Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Patients With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation (AGILE) Recruiting
NCT03176277 Phase I ONO-7475 A Study of ONO-7475 in Patients With Acute Leukemias Recruiting
NCT03187288 Phase I CFI-400945 A Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Recruiting
NCT03190278 Phase I UCART123 Study Evaluating Safety and Efficacy of UCART123 in Patients With Acute Myeloid Leukemia Recruiting
NCT03194685 Phase Ib/II FF-10101 Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia Recruiting
NCT03194932 Phase I Cytarabine Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia Recruiting
NCT03207334 Phase II Cytarabine + Midostaurin iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-BMT-AML-001) Withdrawn
NCT03214562 Phase Ib/II Venetoclax Cytarabine + Filgrastim + Fludarabine + Idarubicin + Venetoclax Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive Acute Myeloid Leukemia (AML) Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) Recruiting
NCT03214666 Phase Ib/II GTB-3550 TriKE GTB-3550 (CD16/IL-15/CD33) Tri-Specific Killer Engager (TriKE) for High Risk Heme Malignancies Recruiting
NCT03217838 Phase Ib/II AZD2811 Safety, Tolerability, and Efficacy of AZD2811 Nanoparticles in Patients With Relapsed AML/High-Risk Myelodysplastic Syndrome or Treatment-Naïve Patients. Recruiting
NCT03224819 Phase I AMG 673 Study of AMG 673 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia Recruiting
NCT03226418 Phase II Cytarabine Decitabine + Venetoclax Azacitidine + Venetoclax CPX-351 Cytarabine + Idarubicin Azacitidine + Glasdegib Decitabine + Glasdegib Cytarabine, Idarubicin, Liposome-encapsulated Daunorubicin-Cytarabine or Decitabine in Treating Older Patients With Acute Myeloid Leukemia Recruiting
NCT03247088 Phase Ib/II Busulfan + Fludarabine + Sorafenib Cyclophosphamide Tacrolimus Filgrastim Study Of Sorafenib Added To Busulfan And Fludarabine Conditioning Regimen In Patients With Relapsed/Refractory AML Undergoing Stem Cell Transplantation Recruiting
NCT03248479 Phase I Azacitidine + Hu5F9-G4 Hu5F9-G4 Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination With Azacitidine in Patients With Hematological Malignancies Recruiting
NCT03250338 Phase III Cytarabine + Filgrastim + Fludarabine + Idarubicin + Mitoxantrone Crenolanib + Cytarabine + Filgrastim + Fludarabine + Idarubicin + Mitoxantrone Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML Recruiting
NCT03263936 Phase I Vorinostat Decitabine Cytarabine Fludarabine Filgrastim Epigenetic Reprogramming in Relapse/Refractory AML Recruiting
NCT03267186 Phase II Ibrutinib Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant Recruiting
NCT03286114 Phase I Pembrolizumab Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab Recruiting
NCT03286530 Phase II Ruxolitinib Ruxolitinib + Allogeneic Stem Cell Transplantation in AML Recruiting
NCT03289910 Phase II Carboplatin + Topotecan + Veliparib Carboplatin + Topotecan Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia Recruiting
NCT03291353 Phase 0 Pembrolizumab Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute Myeloid Leukemia Withdrawn
NCT03298516 Phase I DCLL9718S Azacitidine + DCLL9718S A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy Completed
NCT03298984 Phase I Alvocidib + Cytarabine + Daunorubicin Ph I Study of Alvocidib and Cytarabine/Duanorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML). Recruiting
NCT03303339 Phase Ib/II Decitabine + PCM-075 Cytarabine + Decitabine + PCM-075 Cytarabine + PCM-075 PCM-075 in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML). Recruiting
NCT03315039 Phase Ib/II Liposomal Annamycin Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) Recruiting
NCT03330821 Phase Ib/II Cytarabine + Idarubicin + MLN4924 Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia Recruiting
NCT03335267 Phase II CPX-351 Investigator Initiated Trial of CPX-351 for Untreated Acute Myeloid Leukemia Active, not recruiting
NCT03358719 Phase I DEC-205-NY-ESO-1 fusion protein vaccine + Decitabine + Nivolumab + Poly ICLC DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Active, not recruiting
NCT03360006 Phase I ABBV-744 A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Subjects With Advanced Prostate Cancer (CRPC) and Relapsed/Refractory Acute Myeloid Leukemia (AML) Cancer Recruiting
NCT03365661 Phase II ALT-803 QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML Withdrawn
NCT03374332 Phase II Gemtuzumab ozogamicin Infusional Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Refractory Acute Myeloid Leukemia Recruiting
NCT03386513 Phase I IMGN632 Study of IMGN632 in Patients With Relapse/Refractory AML, BPDCN, ALL, Other CD123+ Hem Malignancies Recruiting
NCT03390296 Phase II Avelumab + Azacitidine + PF-04518600 Azacitidine + PF-04518600 Avelumab + Utomilumab Avelumab + Glasdegib Gemtuzumab ozogamicin + Glasdegib PF-04518600 Avelumab + PF-04518600 PF-04518600 + Utomilumab Pfizer Immunotherapy Combinations for Acute Myeloid Leukemia (AML) Multi-Arm Study 1 Recruiting
NCT03393611 Phase I anti-thymocyte globulin + Fludarabine + Melphalan CPX-351 CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome Recruiting
NCT03395873 Phase I Avelumab + Decitabine Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy Terminated
NCT03397173 Azacitidine TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid Recruiting
NCT03404193 Phase II Decitabine + Venetoclax Venetoclax in Combination With 10-Day Decitabine in Newly Diagnosed Elderly or Relapsed/Refractory Acute Myeloid Leukemia and Relapsed High-risk Myelodysplastic Syndrome Recruiting
NCT03416179 Phase III Cytarabine Cytarabine + Daunorubicin + Glasdegib Azacitidine + Glasdegib Azacitidine Cytarabine + Daunorubicin A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia (BRIGHT AML1019) Recruiting
NCT03417154 Phase II Cyclophosphamide + Nivolumab Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS Suspended
NCT03426605 Phase I LAM-003 A Study of LAM-003 in Patients With Acute Myeloid Leukemia Recruiting
NCT03441555 Phase I Alvocidib + Venetoclax A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia Recruiting
NCT03451084 A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia Recruiting
NCT03459859 Phase I Cytarabine + MLN4924 Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS Recruiting
NCT03466294 Phase II Azacitidine + Venetoclax Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML Recruiting
NCT03471260 Phase Ib/II Ivosidenib + Venetoclax Study of Venetoclax With the mIDH1 Inhibitor Ivosidenib (AG120) in IDH1-Mutated Hematologic Malignancies Recruiting
NCT03483324 Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation Recruiting
NCT03484520 Phase I Dinaciclib + Venetoclax A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia Recruiting
NCT03504410 Phase III Cytarabine + Mitoxantrone CPI-613 + Cytarabine + Mitoxantrone Study Evaluating Efficacy and Safety of CPI-613 in Combination With HD Cytarabine and Mitoxantrone vs HD Cytarabine and Mitoxantrone in Older Patients With R/R AML Recruiting
NCT03512197 Phase III Daunorubicin + Midostaurin Cytarabine + Idarubicin + Midostaurin Cytarabine + Idarubicin Daunorubicin A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML) Recruiting
NCT03513484 Phase I Azacitidine + Nintedanib Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia Recruiting
NCT03515512 Phase I Enasidenib IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation Recruiting
NCT03526926 FDA approved CPX-351 A Post-Marketing Observational Study of VYXEOS Active, not recruiting
NCT03531918 Phase Ib/II Cladribine + Cytarabine + Filgrastim + Gemtuzumab ozogamicin + Mitoxantrone Cladribine + Cytarabine + Filgrastim Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine and Mitoxantrone in Treating Participants With Previously Untreated Acute Myeloid Leukemia or High-Grade Myeloid Neoplasm Recruiting
NCT03537482 Phase I APG-2575 APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies Recruiting
NCT03552029 Phase I DS-3032b + Quizartinib Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML) Recruiting
NCT03557970 Phase II JNJ-40346527 CSF1R Inhibitor JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia Recruiting
NCT03560882 Phase I Atorvastatin A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies Recruiting
NCT03564821 Phase I Ivosidenib IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation Recruiting
NCT03568994 Phase I Atovaquone + Cytarabine + Daunorubicin + Etoposide Atovaquone + Cytarabine + Daunorubicin + Gemtuzumab ozogamicin Atovaquone (Mepron) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML) Recruiting
NCT03573024 Phase II Venetoclax Azacitidine Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemia Recruiting
NCT03586609 Phase II Azacitidine + Cladribine + Cytarabine + Venetoclax Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Participants With Patients Previously Untreated Acute Myeloid Leukemia Recruiting
NCT03591510 Phase II Cytarabine Cytarabine + Etoposide Cytarabine + Mitoxantrone Cytarabine + Fludarabine + Idarubicin Cytarabine + Daunorubicin + Fludarabine Cytarabine + Daunoxome + Fludarabine Midostaurin A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML Suspended
NCT03600155 Phase I Nivolumab Ipilimumab Ipilimumab + Nivolumab Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Participants With High Risk Refractory or Relapsed Acute Myeloid Leukemia Recruiting
NCT03603964 Phase II Guadecitabine Guadecitabine Extension Study Active, not recruiting
NCT03613532 Phase I Busulfan + Fludarabine + Venetoclax Venetoclax Added to Fludarabine + Busulfan Prior to Transplant for AML, MDS, and MDS/MPN Recruiting
NCT03614728 Phase Ib/II Azacitidine + GSK3326595 GSK3326595 Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Recruiting
NCT03616470 Phase III Cytarabine + Etoposide + Mitoxantrone + Uproleselan Cytarabine + Fludarabine + Idarubicin + Uproleselan Cytarabine + Etoposide + Mitoxantrone Cytarabine + Fludarabine + Idarubicin Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia Recruiting
NCT03625505 Phase I Gilteritinib + Venetoclax A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Subjects With Relapsed/Refractory Acute Myeloid Leukemia Recruiting
NCT03629171 Phase II CPX-351 + Venetoclax Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia Recruiting
NCT03634228 Phase Ib/II Cytarabine + DS-3032b MDM2 Inhibitor DS-3032b and Low-Dose Cytarabine in Treating Participants With Newly Diagnosed Recurrent or Refractory Acute Myeloid Leukemia Recruiting
NCT03661307 Phase Ib/II Decitabine Quizartinib and Decitabine in Treating Participants With Untreated or Relapsed FLT3-ITD Mutated Acute Myeloid Leukemia or Myelodysplastic Syndrome Recruiting
NCT03670966 Phase Ib/II BC8-B10 + Cyclophosphamide + Fludarabine Cyclophosphamide + Filgrastim + Mycophenolate mofetil + Sirolimus + Tacrolimus 211At-BC8-B10 and Donor Stem Cell Transplant in Treating Relapsed or Refractory AML, ALL, or Myelodysplastic Syndrome Suspended
NCT03672539 Phase I Gemtuzumab ozogamicin CPX-351 + Gemtuzumab ozogamicin Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome Recruiting
NCT03674411 Phase II Busulfan + Filgrastim + Fludarabine + Melphalan + MGTA-456 + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Filgrastim + Fludarabine + MGTA-456 + Mycophenolate mofetil + Tacrolimus Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy Recruiting
NCT03683433 Phase II Azacitidine + Enasidenib Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation Recruiting
NCT03699384 Phase Ib/II Avelumab + Azacitidine Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD) Withdrawn
NCT03699475 Phase II BPX-501 + Rimiducid Cyclophosphamide Study of Haplo-HSCT + BPX-501 vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS (THRIVE) Suspended
NCT03701295 Phase Ib/II Azacitidine + Pinometostat Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement Recruiting
NCT03701308 Phase II Cytarabine + Daunorubicin Cytarabine + Uproleselan Cytarabine + Daunorubicin + Uproleselan Cytarabine Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy Recruiting
NCT03709576 Phase II Azacitidine + MLN4924 Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission AML Terminated
NCT03709758 Phase I Cytarabine + Daunorubicin + Venetoclax Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naive AML Recruiting
NCT03724084 Phase Ib/II Cytarabine + Daunorubicin + Pinometostat Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement Recruiting
NCT03728335 Phase I Enasidenib Enasidenib as Maintenance Therapy in Treating Patients With Acute Myeloid Leukemia With IDH2 Mutation After Donor Stem Cell Transplant Recruiting
NCT03730012 Phase Ib/II Atezolizumab + Gilteritinib A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML) Recruiting
NCT03735446 Phase I Cytarabine + Etoposide + Mitoxantrone + Prexasertib Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial Terminated
NCT03735875 Phase Ib/II Quizartinib + Venetoclax Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia Recruiting
NCT03737955 Phase II Gemtuzumab ozogamicin Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Participants With Acute Myeloid Leukemia Recruiting
NCT03745352 Phase II Azacitidine Azacitidine + MLN4924 Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Recruiting
NCT03752138 Phase I Decitabine + TK216 TK216 TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia Withdrawn
NCT03760523 Phase I Minnelide Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia Recruiting
NCT03761069 Phase I PTC299 Study of PTC299 in Relapsed/Refractory Acute Leukemias Recruiting
NCT03761914 Phase Ib/II Galinpepimut-S Galinpepimut-S + Pembrolizumab Pembrolizumab Sargramostim Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers Recruiting
NCT03772925 Phase I Belinostat + MLN4924 Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Recruiting
NCT03787498 Phase I PLX2853 A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome Recruiting
NCT03793478 Phase Ib/II Etoposide Cytarabine + Fludarabine + Methotrexate + Prednisolone + Quizartinib Cytarabine + Daunorubicin + Fludarabine + Methotrexate + Prednisolone + Quizartinib Cytarabine + Daunorubicin + Fludarabine + Hydrocortisone + Methotrexate + Quizartinib Cytarabine + Fludarabine + Methotrexate + Prednisolone Quizartinib Safety and Effectiveness of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood Recruiting
NCT03797261 Phase I AMG 176 + Venetoclax A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies Suspended
NCT03807063 Phase I Rimiducid BPX-501 Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant Enrolling by invitation
NCT03813147 Phase I Azacitidine + Cytarabine + Fludarabine + MLN4924 Cytarabine Cytarabine + Hydrocortisone + Methotrexate Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome Recruiting
NCT03825796 Phase II CPX-351 + Enasidenib CPX-351 and Enasidenib in Treating Patients With Relapsed Acute Myeloid Leukemia Characterized by IDH2 Mutation Recruiting
NCT03826992 Phase I CPX-351 + Venetoclax Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia Recruiting
NCT03836209 Phase II Cytarabine + Daunorubicin + Gilteritinib Cytarabine + Daunorubicin + Midostaurin Cytarabine Midostaurin Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia Recruiting
NCT03839446 Phase II Etoposide + Gemtuzumab ozogamicin + Mitoxantrone Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy Recruiting
NCT03843528 Phase I Azacitidine + Vorinostat Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation Recruiting
NCT03844815 Phase I Decitabine + Venetoclax Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia Not yet recruiting
NCT03844997 Phase I CPX-351 + Palbociclib Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia Recruiting
NCT03848754 Phase I Gemtuzumab ozogamicin + Pracinostat Pracinostat in Combination With Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) Recruiting
NCT03850535 Phase Ib/II Cytarabine + Idasanutlin Cytarabine + Daunorubicin + Idasanutlin Idasanutlin A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission Recruiting
NCT03860844 Phase II Idarubicin Cyclophosphamide Isatuximab Doxorubicin Etoposide Daunoxome Cytarabine Methotrexate Daunorubicin Fludarabine Dexamethasone Mitoxantrone Filgrastim Vincristine Pegaspargase Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia Recruiting
NCT03862157 Phase Ib/II Azacitidine + MLN4924 + Venetoclax Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Recruiting
NCT03874052 Phase I Ruxolitinib + Venetoclax Ruxolitinib in Combination With Venetoclax for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia Recruiting
NCT03878199 Phase Ib/II CPX-351 + Ruxolitinib Cytarabine and Daunorubicin in Combination With Ruxolitinib for the Treatment of Secondary Acute Myeloid Leukemia Transformed From Myeloproliferative Neoplasms. Recruiting
NCT03878524 Phase I Oxaliplatin Palbociclib Vemurafenib Sirolimus Tretinoin Celecoxib Ipilimumab Ruxolitinib Dasatinib Abiraterone Idelalisib Trametinib Imatinib Erlotinib Carboplatin Olaparib Panobinostat Bortezomib Afatinib Fluorouracil Vorinostat Pembrolizumab Leucovorin Enzalutamide Ponatinib Nivolumab Everolimus Sunitinib Cabazitaxel Cabozantinib Lenvatinib Pertuzumab Sorafenib Venetoclax Bevacizumab A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia (SMMART) Recruiting
NCT03878927 Phase I CPX-351 + Gemtuzumab ozogamicin CPX-351+GO in Subjects 55 Years Old, or Older, With AML (CPX GO) Suspended
NCT03881735 Phase II Enasidenib Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation Recruiting
NCT03885947 Phase I Cyclophosphamide + Fludarabine + Thiotepa VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies Recruiting
NCT03900949 Phase I Midostaurin Cytarabine Cytarabine + Gemtuzumab ozogamicin Cytarabine + Daunorubicin + Gemtuzumab ozogamicin Testing the Combination of Standard Induction Therapy With Gemtuzumab Ozogamicin and Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia Recruiting
NCT03904069 Phase I Anti-FLT3 CAR-T cells Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML Not yet recruiting
NCT03904251 Phase I CPX-351 + Gemtuzumab ozogamicin CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia Recruiting
NCT03912064 Phase I Ipilimumab A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT Recruiting
NCT03913026 Phase II ECT-001 cord blood cells Mycophenolate mofetil Tacrolimus Cyclophosphamide + Fludarabine Cyclophosphamide + Fludarabine + Thiotepa UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia Recruiting
NCT03922477 Phase I Atezolizumab + Hu5F9-G4 A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia Recruiting
NCT03927261 PRGN-3006 Adoptive Cellular Therapy Relapsed or Refractory AML or High Risk MDS Recruiting
NCT03931291 Phase II APR-246 + Azacitidine APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant Recruiting
NCT03932643 Phase I ONC201 ONC 201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant Recruiting
NCT03940352 Phase I HDM201 + Venetoclax HDM201 + MBG453 HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS) Recruiting
NCT03941964 Phase III Decitabine + Venetoclax Azacitidine + Venetoclax A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Recruiting
NCT03955783 Phase I Selinexor + Venetoclax Venetoclax and Selinexor in Treating Patients With Relapsed or Refractory High Risk Hematologic Malignancies Recruiting
NCT03969420 Phase II Alvocidib + Cytarabine Alvocidib Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy Recruiting
NCT03969446 Phase I Decitabine + Pembrolizumab Pembrolizumab and Decitabine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory Not yet recruiting
NCT03974217 Phase I Talazoparib Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts Recruiting
NCT03983824 Phase I Cytarabine + Etoposide + Mitoxantrone + MSC2490484A Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia Recruiting
NCT03988205 FDA approved CPX-351 Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia Recruiting
NCT04013880 Phase Ib/II ASTX727 + FT-2102 ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia Recruiting
NCT04021368 Phase I SEL120-34A SEL120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Recruiting
NCT04022785 Phase I Azacitidine + PLX51107 PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Recruiting
NCT04023071 Phase I Aldesleukin + Cyclophosphamide + Fludarabine + FT516 + Obinutuzumab Aldesleukin + Cyclophosphamide + Fludarabine + FT516 + Rituximab Aldesleukin + Cyclophosphamide + Fludarabine + FT516 FT516 in Subjects With Advanced Hematologic Malignancies Recruiting
NCT04023526 Phase II ARGX-110 + Azacitidine A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy Recruiting
NCT04029688 Phase Ib/II Idasanutlin + Venetoclax Cyclophosphamide + Idasanutlin + Topotecan Cytarabine + Fludarabine + Idasanutlin Cytarabine + Hydrocortisone + Methotrexate Cytarabine Methotrexate Idasanutlin Cyclophosphamide + Idasanutlin A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in the Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors Recruiting
NCT04047641 Phase II Quizartinib Cladribine + Cytarabine + Idarubicin + Quizartinib Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Recruiting
NCT04049539 Phase II CPX-351 Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction Not yet recruiting
NCT04051996 Phase II Decitabine + Glasdegib GLASDEGIB (PF-04449913) WITH TWO STANDARD DECITABINE REGIMENS Recruiting
NCT04055844 Phase II Decitabine + Ruxolitinib Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS Recruiting
NCT04062266 Phase II Azacitidine + Venetoclax Azacitidine and Venetoclax in Treating Patients With High Risk Acute Myeloid Leukemia in Remission Recruiting
NCT04065399 Phase Ib/II SNDX-5613 A Study of SNDX-5613 in R/R Leukemias Including Those With an MLLr/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101) Recruiting
NCT04067336 Phase I KO-539 First in Human Study of KO-539 in Relapsed or Refractory Acute Myeloid Leukemia Recruiting
NCT04070768 Phase I Gemtuzumab ozogamicin + Venetoclax Venetoclax Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113 Recruiting
NCT04075747 Phase I CPX-351 + Enasidenib CPX-351 + Venetoclax CPX-351 + Midostaurin A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia (V-FAST) Recruiting
NCT04079738 Phase Ib/II Ixazomib + TAK-659 Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib Recruiting
NCT04081259 Phase I LY3214996 LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy Not yet recruiting
NCT04086264 Phase Ib/II IMGN632 IMGN632 + Venetoclax Azacitidine + IMGN632 Azacitidine + IMGN632 + Venetoclax IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Patients With CD123-Positive Acute Myeloid Leukemia Recruiting
NCT04092179 Phase Ib/II Enasidenib + Venetoclax Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers Not yet recruiting
NCT04102020 Phase III Azacitidine + Venetoclax A Safety and Efficacy Study of Oral Venetoclax Tablets and Injectable Azacitidine Versus Best Supportive Care as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy to Evaluate Improvement in Relapse-Free Survival (VIALE-M) Recruiting
NCT04103879 Phase II ECT-001 cord blood cells Cyclophosphamide + Fludarabine + Thiotepa Tacrolimus Cyclophosphamide + Fludarabine Mycophenolate mofetil US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia Recruiting
NCT04109482 Phase Ib/II Cyclophosphamide + Decitabine + Fludarabine + MB-102 Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN, AML, and hrMDS. Recruiting
NCT04113616 Phase Ib/II Decitabine + KRT-232 Cytarabine + KRT-232 An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML) Recruiting
NCT04128020 Phase I Azacitidine + Nivolumab Nivolumab Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia Recruiting
NCT04128501 Phase II Azacitidine + Venetoclax Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting Not yet recruiting
NCT04128748 Phase Ib/II CPX-351 + Quizartinib Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome Not yet recruiting
NCT04139434 Phase I LP-108 Dose-escalation Study of Oral Administration of LP-108 in Patients With Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) Not yet recruiting
NCT04140487 Phase Ib/II Azacitidine + Gilteritinib + Venetoclax Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Recruiting
NCT04146038 Phase II Decitabine + Salsalate + Venetoclax Azacitidine + Salsalate + Venetoclax Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease Not yet recruiting
NCT04150887 Phase I ARGX-110 + Azacitidine + Venetoclax ARGX-110 + Venetoclax ARGX-110 + Azacitidine Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia Recruiting
NCT04158739 Phase I Cytarabine + Flotetuzumab Flotetuzumab and Cytarabine for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia Recruiting
NCT04161885 Phase III Azacitidine + Venetoclax A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) (VIALE-T) Recruiting
NCT04172844 Phase I Azacitidine + MLN4924 + Venetoclax Pevonedistat, Azacitidine, and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia (PAVE) Recruiting
NCT04188405 Phase II Decitabine + Ponatinib + Venetoclax Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase Chronic Myelogenous Leukemia Not yet recruiting
NCT04195945 Phase II CPX-351 Cladribine + Cytarabine + Filgrastim + Mitoxantrone CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients Recruiting
NCT04207190 Phase Ib/II Gemtuzumab ozogamicin + Talazoparib Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia Not yet recruiting
NCT04209725 Phase II CPX-351 + Quizartinib A Study of CPX-351 (Vyxeos) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia Not yet recruiting
NCT04214860 Phase I APR-246 + Azacitidine + Venetoclax APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies Recruiting
NCT04229979 Phase III Galinpepimut-S Cytarabine Decitabine Venetoclax Azacitidine GPS Compared With BAT in AML CR2/CR2p Recruiting
NCT04231851 Phase II CPX-351 + Glasdegib CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia Not yet recruiting
NCT04240002 Phase Ib/II Cytarabine + Filgrastim + Fludarabine + Gilteritinib A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) Recruiting
NCT04243785 A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Recruiting
NCT04250051 Phase I Cytarabine + Filgrastim + Fludarabine + Ivosidenib Ivosidenib Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia Not yet recruiting
NCT04272203 Phase I ABBV-184 Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers Recruiting
NCT04277442 Phase I Decitabine + Nivolumab + Venetoclax Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia Recruiting
NCT04278768 Phase I CA-4948 An Open Label Dose Escalation Trial of CA-4948 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Recruiting
NCT04284228 Phase Ib/II Cyclophosphamide + Fludarabine + NEXI-001 T Cells Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT Recruiting
NCT04318678 Phase I Cyclophosphamide + Fludarabine + MB-102 + Mesna + Rituximab CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML) ((CATCHAML)) Not yet recruiting